Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
U.S. cancer detection severely disrupted during first year of COVID-19, shows incomplete recovery in second year

U.S. cancer detection severely disrupted during first year of COVID-19, shows incomplete recovery in second year

Study links monoclonal B-cell lymphocytosis to elevated melanoma risk

Study links monoclonal B-cell lymphocytosis to elevated melanoma risk

Review of fasting-mimicking diets in cancer treatment

Review of fasting-mimicking diets in cancer treatment

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Research unveils bispecific antibodies for B-cell lymphoma treatment

Research unveils bispecific antibodies for B-cell lymphoma treatment

Study evaluates the feasibility of discontinuing CLL specialist care

Study evaluates the feasibility of discontinuing CLL specialist care

New Blood Cancer Healing Center poised to redefine care standards

New Blood Cancer Healing Center poised to redefine care standards

Combination treatments reduce blood pressure in patients taking ibrutinib

Combination treatments reduce blood pressure in patients taking ibrutinib

Next-gen BTK degrader could help overcome treatment resistance in chronic lymphocytic leukemia

Next-gen BTK degrader could help overcome treatment resistance in chronic lymphocytic leukemia

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Personalized treatment for leukemia results in longer life and fewer side effects

Personalized treatment for leukemia results in longer life and fewer side effects

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

As covid infections rise, nursing homes are still waiting for vaccines

As covid infections rise, nursing homes are still waiting for vaccines

Annual NCCN Congress to focus on latest advances in blood cancer treatment

Annual NCCN Congress to focus on latest advances in blood cancer treatment

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

Research reveals therapeutic potential of novel compound in inhibiting oncogene translation

Research reveals therapeutic potential of novel compound in inhibiting oncogene translation

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Ultra-processed food and cancer: is there a link?

Ultra-processed food and cancer: is there a link?

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.